Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
Background: In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40–80 % (Volz et al.,...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Epidemics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1755436521000335 |
id |
doaj-bd41319829ad4201b8f18a7bf5efe47f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chaoran Chen Sarah Ann Nadeau Ivan Topolsky Marc Manceau Jana S. Huisman Kim Philipp Jablonski Lara Fuhrmann David Dreifuss Katharina Jahn Christiane Beckmann Maurice Redondo Christoph Noppen Lorenz Risch Martin Risch Nadia Wohlwend Sinem Kas Thomas Bodmer Tim Roloff Madlen Stange Adrian Egli Isabella Eckerle Laurent Kaiser Rebecca Denes Mirjam Feldkamp Ina Nissen Natascha Santacroce Elodie Burcklen Catharine Aquino Andreia Cabral de Gouvea Maria Domenica Moccia Simon Grüter Timothy Sykes Lennart Opitz Griffin White Laura Neff Doris Popovic Andrea Patrignani Jay Tracy Ralph Schlapbach Emmanouil T. Dermitzakis Keith Harshman Ioannis Xenarios Henri Pegeot Lorenzo Cerutti Deborah Penet Anthony Blin Melyssa Elies Christian L. Althaus Christian Beisel Niko Beerenwinkel Martin Ackermann Tanja Stadler |
spellingShingle |
Chaoran Chen Sarah Ann Nadeau Ivan Topolsky Marc Manceau Jana S. Huisman Kim Philipp Jablonski Lara Fuhrmann David Dreifuss Katharina Jahn Christiane Beckmann Maurice Redondo Christoph Noppen Lorenz Risch Martin Risch Nadia Wohlwend Sinem Kas Thomas Bodmer Tim Roloff Madlen Stange Adrian Egli Isabella Eckerle Laurent Kaiser Rebecca Denes Mirjam Feldkamp Ina Nissen Natascha Santacroce Elodie Burcklen Catharine Aquino Andreia Cabral de Gouvea Maria Domenica Moccia Simon Grüter Timothy Sykes Lennart Opitz Griffin White Laura Neff Doris Popovic Andrea Patrignani Jay Tracy Ralph Schlapbach Emmanouil T. Dermitzakis Keith Harshman Ioannis Xenarios Henri Pegeot Lorenzo Cerutti Deborah Penet Anthony Blin Melyssa Elies Christian L. Althaus Christian Beisel Niko Beerenwinkel Martin Ackermann Tanja Stadler Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland Epidemics Pandemic SARS-CoV-2 COVID-19 B.1.1.7 Transmission advantage |
author_facet |
Chaoran Chen Sarah Ann Nadeau Ivan Topolsky Marc Manceau Jana S. Huisman Kim Philipp Jablonski Lara Fuhrmann David Dreifuss Katharina Jahn Christiane Beckmann Maurice Redondo Christoph Noppen Lorenz Risch Martin Risch Nadia Wohlwend Sinem Kas Thomas Bodmer Tim Roloff Madlen Stange Adrian Egli Isabella Eckerle Laurent Kaiser Rebecca Denes Mirjam Feldkamp Ina Nissen Natascha Santacroce Elodie Burcklen Catharine Aquino Andreia Cabral de Gouvea Maria Domenica Moccia Simon Grüter Timothy Sykes Lennart Opitz Griffin White Laura Neff Doris Popovic Andrea Patrignani Jay Tracy Ralph Schlapbach Emmanouil T. Dermitzakis Keith Harshman Ioannis Xenarios Henri Pegeot Lorenzo Cerutti Deborah Penet Anthony Blin Melyssa Elies Christian L. Althaus Christian Beisel Niko Beerenwinkel Martin Ackermann Tanja Stadler |
author_sort |
Chaoran Chen |
title |
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland |
title_short |
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland |
title_full |
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland |
title_fullStr |
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland |
title_full_unstemmed |
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland |
title_sort |
quantification of the spread of sars-cov-2 variant b.1.1.7 in switzerland |
publisher |
Elsevier |
series |
Epidemics |
issn |
1755-4365 |
publishDate |
2021-12-01 |
description |
Background: In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40–80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 2021). Aim: This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. Methods: We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale. Results: We estimate B.1.1.7 had a transmission fitness advantage of 43–52 % compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07–1.41] from 01 January until 17 January 2021 and 1.18 [1.06–1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00–1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021. Conclusion: The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2–3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online. |
topic |
Pandemic SARS-CoV-2 COVID-19 B.1.1.7 Transmission advantage |
url |
http://www.sciencedirect.com/science/article/pii/S1755436521000335 |
work_keys_str_mv |
AT chaoranchen quantificationofthespreadofsarscov2variantb117inswitzerland AT sarahannnadeau quantificationofthespreadofsarscov2variantb117inswitzerland AT ivantopolsky quantificationofthespreadofsarscov2variantb117inswitzerland AT marcmanceau quantificationofthespreadofsarscov2variantb117inswitzerland AT janashuisman quantificationofthespreadofsarscov2variantb117inswitzerland AT kimphilippjablonski quantificationofthespreadofsarscov2variantb117inswitzerland AT larafuhrmann quantificationofthespreadofsarscov2variantb117inswitzerland AT daviddreifuss quantificationofthespreadofsarscov2variantb117inswitzerland AT katharinajahn quantificationofthespreadofsarscov2variantb117inswitzerland AT christianebeckmann quantificationofthespreadofsarscov2variantb117inswitzerland AT mauriceredondo quantificationofthespreadofsarscov2variantb117inswitzerland AT christophnoppen quantificationofthespreadofsarscov2variantb117inswitzerland AT lorenzrisch quantificationofthespreadofsarscov2variantb117inswitzerland AT martinrisch quantificationofthespreadofsarscov2variantb117inswitzerland AT nadiawohlwend quantificationofthespreadofsarscov2variantb117inswitzerland AT sinemkas quantificationofthespreadofsarscov2variantb117inswitzerland AT thomasbodmer quantificationofthespreadofsarscov2variantb117inswitzerland AT timroloff quantificationofthespreadofsarscov2variantb117inswitzerland AT madlenstange quantificationofthespreadofsarscov2variantb117inswitzerland AT adrianegli quantificationofthespreadofsarscov2variantb117inswitzerland AT isabellaeckerle quantificationofthespreadofsarscov2variantb117inswitzerland AT laurentkaiser quantificationofthespreadofsarscov2variantb117inswitzerland AT rebeccadenes quantificationofthespreadofsarscov2variantb117inswitzerland AT mirjamfeldkamp quantificationofthespreadofsarscov2variantb117inswitzerland AT inanissen quantificationofthespreadofsarscov2variantb117inswitzerland AT nataschasantacroce quantificationofthespreadofsarscov2variantb117inswitzerland AT elodieburcklen quantificationofthespreadofsarscov2variantb117inswitzerland AT catharineaquino quantificationofthespreadofsarscov2variantb117inswitzerland AT andreiacabraldegouvea quantificationofthespreadofsarscov2variantb117inswitzerland AT mariadomenicamoccia quantificationofthespreadofsarscov2variantb117inswitzerland AT simongruter quantificationofthespreadofsarscov2variantb117inswitzerland AT timothysykes quantificationofthespreadofsarscov2variantb117inswitzerland AT lennartopitz quantificationofthespreadofsarscov2variantb117inswitzerland AT griffinwhite quantificationofthespreadofsarscov2variantb117inswitzerland AT lauraneff quantificationofthespreadofsarscov2variantb117inswitzerland AT dorispopovic quantificationofthespreadofsarscov2variantb117inswitzerland AT andreapatrignani quantificationofthespreadofsarscov2variantb117inswitzerland AT jaytracy quantificationofthespreadofsarscov2variantb117inswitzerland AT ralphschlapbach quantificationofthespreadofsarscov2variantb117inswitzerland AT emmanouiltdermitzakis quantificationofthespreadofsarscov2variantb117inswitzerland AT keithharshman quantificationofthespreadofsarscov2variantb117inswitzerland AT ioannisxenarios quantificationofthespreadofsarscov2variantb117inswitzerland AT henripegeot quantificationofthespreadofsarscov2variantb117inswitzerland AT lorenzocerutti quantificationofthespreadofsarscov2variantb117inswitzerland AT deborahpenet quantificationofthespreadofsarscov2variantb117inswitzerland AT anthonyblin quantificationofthespreadofsarscov2variantb117inswitzerland AT melyssaelies quantificationofthespreadofsarscov2variantb117inswitzerland AT christianlalthaus quantificationofthespreadofsarscov2variantb117inswitzerland AT christianbeisel quantificationofthespreadofsarscov2variantb117inswitzerland AT nikobeerenwinkel quantificationofthespreadofsarscov2variantb117inswitzerland AT martinackermann quantificationofthespreadofsarscov2variantb117inswitzerland AT tanjastadler quantificationofthespreadofsarscov2variantb117inswitzerland |
_version_ |
1717814600483733504 |
spelling |
doaj-bd41319829ad4201b8f18a7bf5efe47f2021-09-05T04:40:04ZengElsevierEpidemics1755-43652021-12-0137100480Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in SwitzerlandChaoran Chen0Sarah Ann Nadeau1Ivan Topolsky2Marc Manceau3Jana S. Huisman4Kim Philipp Jablonski5Lara Fuhrmann6David Dreifuss7Katharina Jahn8Christiane Beckmann9Maurice Redondo10Christoph Noppen11Lorenz Risch12Martin Risch13Nadia Wohlwend14Sinem Kas15Thomas Bodmer16Tim Roloff17Madlen Stange18Adrian Egli19Isabella Eckerle20Laurent Kaiser21Rebecca Denes22Mirjam Feldkamp23Ina Nissen24Natascha Santacroce25Elodie Burcklen26Catharine Aquino27Andreia Cabral de Gouvea28Maria Domenica Moccia29Simon Grüter30Timothy Sykes31Lennart Opitz32Griffin White33Laura Neff34Doris Popovic35Andrea Patrignani36Jay Tracy37Ralph Schlapbach38Emmanouil T. Dermitzakis39Keith Harshman40Ioannis Xenarios41Henri Pegeot42Lorenzo Cerutti43Deborah Penet44Anthony Blin45Melyssa Elies46Christian L. Althaus47Christian Beisel48Niko Beerenwinkel49Martin Ackermann50Tanja Stadler51Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, Switzerland; Department of Environmental Systems Science, ETH Zürich, Swiss Federal Institute of Technology, Zurich, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandViollier AG, Allschwil, SwitzerlandViollier AG, Allschwil, SwitzerlandViollier AG, Allschwil, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandSwiss Institute of Bioinformatics, Switzerland; Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland; Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, SwitzerlandSwiss Institute of Bioinformatics, Switzerland; Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland; Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, SwitzerlandClinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland; Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, SwitzerlandGeneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland; Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandGeneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland; Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandHealth 2030 Genome Center, Geneva, Switzerland; University of Geneva Medical School, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Department of Environmental Microbiology, Eawag, Dubendorf, SwitzerlandHealth 2030 Genome Center, Geneva, Switzerland; University of Geneva Medical School, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandInstitute of Social and Preventive Medicine, University of Bern, Bern, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Environmental Systems Science, ETH Zürich, Swiss Federal Institute of Technology, Zurich, Switzerland; Department of Environmental Microbiology, Eawag, Dubendorf, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, Switzerland; Corresponding author at: Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.Background: In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40–80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 2021). Aim: This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. Methods: We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale. Results: We estimate B.1.1.7 had a transmission fitness advantage of 43–52 % compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07–1.41] from 01 January until 17 January 2021 and 1.18 [1.06–1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00–1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021. Conclusion: The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2–3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.http://www.sciencedirect.com/science/article/pii/S1755436521000335PandemicSARS-CoV-2COVID-19B.1.1.7Transmission advantage |